Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis

Author:

Ling Yunzhi1,Zhong Jiaying2,Luo Jiaru2

Affiliation:

1. Department of Infectious Disease, Center Lab of Longhua Branch, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital Southern University of Science and Technology Shenzhen Guangdong China

2. Department of Research Center Algae Company Guangzhou China

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference20 articles.

1. World Health Organization. Draft landscape and tracker of COVID‐19 candidate vaccines.https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.2021.

2. China grants conditional approval for first COVID vaccine.http://english.nmpa.gov.cn/2020-12/31/c_579192.htm.2020.

3. NMPA conditionally approves COVID‐19 vaccine developed by Sinopharm's Wuhan Institute.http://english.nmpa.gov.cn/2021-02/27/c_597152.htm.2021.

4. Sinovac COVID‐19 vaccine granted conditional market approval in China.http://english.nmpa.gov.cn/2021-02/07/c_588422.htm.2021.

5. Pfizer and BioNTech Receive authorization in the European Union for COVID‐19 vaccine.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union.2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3